Indication
Fabrazyme is indicated for long-term enzyme replacement therapy in patients with a confirmed diagnosis of Fabry disease (?-galactosidase-A deficiency).
Loading your page…
Loading your page…
Fabry Disease
Marketing Authorisation Holder: Sanofi B.V.
EMA Authorisation: 03/08/2001
INN: agalsidase beta
AI Drug & Interaction Analysis
Free account required
Ask Osler about Fabrazyme: drug interactions and guideline evidence, with every claim numbered to its source. For reference and learning, not treatment advice.
Medical disclaimer: This information is intended for qualified healthcare professionals. Always verify with the official EMA Summary of Product Characteristics (SmPC) before clinical use.